The global market for Critical Care Therapeutics was valued at US$ 3061 million in the year 2024 and is projected to reach a revised size of US$ 3576 million by 2031, growing at a CAGR of 2.3% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Critical Care Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Critical Care Therapeutics.
The Critical Care Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Critical Care Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Critical Care Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
CSL Behring
Grifols
Kedrion Biopharma
Octapharma
Takeda
Bayer HealthCare
Merck
Mitsubishi Tanabe Pharma
REVO Biologics
Rockwell Medical
Thermo Fisher Scientific
Shanghai RAAS
China Biologic Products
Cosmo Pharmaceuticals
King Pharmaceuticals
Segment by Type
Albumin
Prothrombin Complex Concentrates
Antithrombin Concentrates
Factor XIII Concentrates
Fibrinogen Concentrates
Segment by Application
Pulmonary Embolism (PE)
Acute Coronary Syndrome
Atrial Fibrillation
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Critical Care Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Critical Care Therapeutics 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Albumin
1.2.3 Prothrombin Complex Concentrates
1.2.4 Antithrombin Concentrates
1.2.5 Factor XIII Concentrates
1.2.6 Fibrinogen Concentrates
1.3 麻豆原创 by Application
1.3.1 Global Critical Care Therapeutics 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pulmonary Embolism (PE)
1.3.3 Acute Coronary Syndrome
1.3.4 Atrial Fibrillation
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Critical Care Therapeutics 麻豆原创 Perspective (2020-2031)
2.2 Global Critical Care Therapeutics Growth Trends by Region
2.2.1 Global Critical Care Therapeutics 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Critical Care Therapeutics Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Critical Care Therapeutics Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Critical Care Therapeutics 麻豆原创 Dynamics
2.3.1 Critical Care Therapeutics Industry Trends
2.3.2 Critical Care Therapeutics 麻豆原创 Drivers
2.3.3 Critical Care Therapeutics 麻豆原创 Challenges
2.3.4 Critical Care Therapeutics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Critical Care Therapeutics Players by Revenue
3.1.1 Global Top Critical Care Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Critical Care Therapeutics Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Critical Care Therapeutics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Critical Care Therapeutics Revenue
3.4 Global Critical Care Therapeutics 麻豆原创 Concentration Ratio
3.4.1 Global Critical Care Therapeutics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Critical Care Therapeutics Revenue in 2024
3.5 Global Key Players of Critical Care Therapeutics Head office and Area Served
3.6 Global Key Players of Critical Care Therapeutics, Product and Application
3.7 Global Key Players of Critical Care Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Critical Care Therapeutics Breakdown Data by Type
4.1 Global Critical Care Therapeutics Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Critical Care Therapeutics Forecasted 麻豆原创 Size by Type (2026-2031)
5 Critical Care Therapeutics Breakdown Data by Application
5.1 Global Critical Care Therapeutics Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Critical Care Therapeutics Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Critical Care Therapeutics 麻豆原创 Size (2020-2031)
6.2 North America Critical Care Therapeutics 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Critical Care Therapeutics 麻豆原创 Size by Country (2020-2025)
6.4 North America Critical Care Therapeutics 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Critical Care Therapeutics 麻豆原创 Size (2020-2031)
7.2 Europe Critical Care Therapeutics 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Critical Care Therapeutics 麻豆原创 Size by Country (2020-2025)
7.4 Europe Critical Care Therapeutics 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Critical Care Therapeutics 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Critical Care Therapeutics 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Critical Care Therapeutics 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Critical Care Therapeutics 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Critical Care Therapeutics 麻豆原创 Size (2020-2031)
9.2 Latin America Critical Care Therapeutics 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Critical Care Therapeutics 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Critical Care Therapeutics 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Critical Care Therapeutics 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Critical Care Therapeutics 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Critical Care Therapeutics 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Critical Care Therapeutics 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 CSL Behring
11.1.1 CSL Behring Company Details
11.1.2 CSL Behring Business Overview
11.1.3 CSL Behring Critical Care Therapeutics Introduction
11.1.4 CSL Behring Revenue in Critical Care Therapeutics Business (2020-2025)
11.1.5 CSL Behring Recent Development
11.2 Grifols
11.2.1 Grifols Company Details
11.2.2 Grifols Business Overview
11.2.3 Grifols Critical Care Therapeutics Introduction
11.2.4 Grifols Revenue in Critical Care Therapeutics Business (2020-2025)
11.2.5 Grifols Recent Development
11.3 Kedrion Biopharma
11.3.1 Kedrion Biopharma Company Details
11.3.2 Kedrion Biopharma Business Overview
11.3.3 Kedrion Biopharma Critical Care Therapeutics Introduction
11.3.4 Kedrion Biopharma Revenue in Critical Care Therapeutics Business (2020-2025)
11.3.5 Kedrion Biopharma Recent Development
11.4 Octapharma
11.4.1 Octapharma Company Details
11.4.2 Octapharma Business Overview
11.4.3 Octapharma Critical Care Therapeutics Introduction
11.4.4 Octapharma Revenue in Critical Care Therapeutics Business (2020-2025)
11.4.5 Octapharma Recent Development
11.5 Takeda
11.5.1 Takeda Company Details
11.5.2 Takeda Business Overview
11.5.3 Takeda Critical Care Therapeutics Introduction
11.5.4 Takeda Revenue in Critical Care Therapeutics Business (2020-2025)
11.5.5 Takeda Recent Development
11.6 Bayer HealthCare
11.6.1 Bayer HealthCare Company Details
11.6.2 Bayer HealthCare Business Overview
11.6.3 Bayer HealthCare Critical Care Therapeutics Introduction
11.6.4 Bayer HealthCare Revenue in Critical Care Therapeutics Business (2020-2025)
11.6.5 Bayer HealthCare Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Critical Care Therapeutics Introduction
11.7.4 Merck Revenue in Critical Care Therapeutics Business (2020-2025)
11.7.5 Merck Recent Development
11.8 Mitsubishi Tanabe Pharma
11.8.1 Mitsubishi Tanabe Pharma Company Details
11.8.2 Mitsubishi Tanabe Pharma Business Overview
11.8.3 Mitsubishi Tanabe Pharma Critical Care Therapeutics Introduction
11.8.4 Mitsubishi Tanabe Pharma Revenue in Critical Care Therapeutics Business (2020-2025)
11.8.5 Mitsubishi Tanabe Pharma Recent Development
11.9 REVO Biologics
11.9.1 REVO Biologics Company Details
11.9.2 REVO Biologics Business Overview
11.9.3 REVO Biologics Critical Care Therapeutics Introduction
11.9.4 REVO Biologics Revenue in Critical Care Therapeutics Business (2020-2025)
11.9.5 REVO Biologics Recent Development
11.10 Rockwell Medical
11.10.1 Rockwell Medical Company Details
11.10.2 Rockwell Medical Business Overview
11.10.3 Rockwell Medical Critical Care Therapeutics Introduction
11.10.4 Rockwell Medical Revenue in Critical Care Therapeutics Business (2020-2025)
11.10.5 Rockwell Medical Recent Development
11.11 Thermo Fisher Scientific
11.11.1 Thermo Fisher Scientific Company Details
11.11.2 Thermo Fisher Scientific Business Overview
11.11.3 Thermo Fisher Scientific Critical Care Therapeutics Introduction
11.11.4 Thermo Fisher Scientific Revenue in Critical Care Therapeutics Business (2020-2025)
11.11.5 Thermo Fisher Scientific Recent Development
11.12 Shanghai RAAS
11.12.1 Shanghai RAAS Company Details
11.12.2 Shanghai RAAS Business Overview
11.12.3 Shanghai RAAS Critical Care Therapeutics Introduction
11.12.4 Shanghai RAAS Revenue in Critical Care Therapeutics Business (2020-2025)
11.12.5 Shanghai RAAS Recent Development
11.13 China Biologic Products
11.13.1 China Biologic Products Company Details
11.13.2 China Biologic Products Business Overview
11.13.3 China Biologic Products Critical Care Therapeutics Introduction
11.13.4 China Biologic Products Revenue in Critical Care Therapeutics Business (2020-2025)
11.13.5 China Biologic Products Recent Development
11.14 Cosmo Pharmaceuticals
11.14.1 Cosmo Pharmaceuticals Company Details
11.14.2 Cosmo Pharmaceuticals Business Overview
11.14.3 Cosmo Pharmaceuticals Critical Care Therapeutics Introduction
11.14.4 Cosmo Pharmaceuticals Revenue in Critical Care Therapeutics Business (2020-2025)
11.14.5 Cosmo Pharmaceuticals Recent Development
11.15 King Pharmaceuticals
11.15.1 King Pharmaceuticals Company Details
11.15.2 King Pharmaceuticals Business Overview
11.15.3 King Pharmaceuticals Critical Care Therapeutics Introduction
11.15.4 King Pharmaceuticals Revenue in Critical Care Therapeutics Business (2020-2025)
11.15.5 King Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
CSL Behring
Grifols
Kedrion Biopharma
Octapharma
Takeda
Bayer HealthCare
Merck
Mitsubishi Tanabe Pharma
REVO Biologics
Rockwell Medical
Thermo Fisher Scientific
Shanghai RAAS
China Biologic Products
Cosmo Pharmaceuticals
King Pharmaceuticals
听
听
*If Applicable.
